anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study will involve healthy smokers and non smokers enrolled in IRB approved protocol #0005004439 entitled "Evaluation of the Lungs of Normal (Smokers, Ex-smokers, Non-Smokers) Individuals with Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing, and Bronchial Wall Biopsy". They will be invited to participate in this protocol only if they meet the additional inclusion/exclusion criteria of this protocol (see inclusion/exclusion criteria, section A6). The Principal Investigator, Ann E. Tilley, MD or authorized representative will obtain consent from individuals for this study. Once enrolled, smokers will be randomized to either the treated smoker group \[320 micrograms (mcg) of beclomethasone; 2 puffs twice a day (each puff delivers 80 mcg) for 7 days\] or non-treated group. Beclomethasone is available as a metered dose inhaler \[QVAR(TEVA Pharmaceuticals)\] delivering 80 micrograms (mcg) of beclomethasone per one puff. We will be using QVAR HFA (TEVA Pharmaceuticals), which delivers 80 mcg per puff. QVAR will be purchased by the Department of Genetic Medicine. It will be dispensed as appropriate to each research subject recruited in the trial at the Department of Genetic Medicine at 1305 York Ave YAB-13th floor, New York, NY 10021 (a facility of Weill Medical College). It will be stored at The Arthur \& Rochelle Belfer Gene Therapy Core Facility located at 515 E. 71st St., S901, New York, NY 10021 under the supervision of Stephen Kaminksy, PhD, Co-Director of the GMP (Good Manufacturing Practice). Each study individual will receive 1 package of the study medication which consists of 1 canister of QVAR 80 MDI (metered dose inhaler). Non-smokers, defined as individuals who have never smoked, will act as control like the Non-Treated Smoker group and receive no treatment. For all subjects, the screening, baseline bronchoscopy, and the bronchoscopies on Days 7±3 and 14±3 tests will be performed as part of IRB approved protocol #0005004439. No additional bronchoscopies will be performed under the current protocol.
For parents of children with epilepsy, seizures occurring in sleep are a major concern. This frequently leads to many nights of lost sleep for parents and also to unfavorable sleeping arrangements, especially for older children and adolescents. Sudden unexplained death in epilepsy patients (SUDEP) is also a major concern for both parents and neurology practitioners. Patients with epilepsy have increased risk of sudden unexplained death compared to the rest of the population. The risk of sudden death in epilepsy is estimated at 24 times the risk of the general population. Specific risk factors for sudden death have been evaluated and the most frequently reported risk factors include: nocturnal seizures, being in bed, and history of generalized tonic -clonic seizures. Interestingly, one case-control study observed a decreased risk of SUDEP with nighttime monitoring or supervision which raises the possibility that some cases of SUDEP may be preventable if another person is able to give assistance. This finding may indicate that some of these deaths may be preventable if a caregiver could be alerted to seizure activity. Use of "baby monitors", apnea monitors and pulse oximeters to monitor their children at night has been attempted by families; however, these devices are not specific to seizure activity and in the case of apnea monitors and pulse oximeters have frequent false alarms leading to further anxiety and sleep disturbance for families. Therefore, there is a need for a product that can reliably detect seizure activity without such frequent false positives as to interfere with sleep and functional life.
Participants watch 2 educational videos during week 3 regarding air pollution, health effects, and personal preventive health behaviors to reduce air pollution exposure. Participants will use wearable air pollution sensors. Participants will complete questionnaires at weeks 1 and 5.
A composition comprising a sourdough and a mixture of microorganisms consisting of a Lactobacilli acidophilus strain, a Bifidobacterium infantis strain, an Enterococcus faecium strain and a Bifidum bifidum strain. The composition may further comprise vitamin(s) and/or mineral(s), particularly vitamin D3 and K2, calcium carbonate, calcium citrate, tricalcium phosphate and silicon dioxide. The composition may further comprise an enzyme such as a phytase, particularly a bacterial phytase from Lactobacillus reuteri or Buttiauxella. A food product or supplement is also claimed, which may be a sourdough or a beverage. The composition or food product may be used in human or veterinary medicine. The composition or food product may be used in the prevention and/or treatment of intestinal disease, improvement of intestinal health and promoting healthy gut flora, the prevention and/or treatment of bone disorders and the improvement of bone health, in particular for the prevention and/or treatment of osteoporosis; it is disclosed that this may be due to the addition of a further phytase.
This study is going to look at the effectiveness of Bowen Therapy in pain management for patients with fibromyalgia. 80 patients with fibromyalgia attending pain management clinic will be recruited at Alice Ho Miu Ling Nethersole Hospital after informed consent. They will be randomized into either group (control group or Bowen group). Control group will continue receiving conventional treatment such as follow-ups by pain specialists, taking analgesia, physiotherapy. Bowen group will need to attend 8 sessions of therapy. All subjects will be evaluated at 12th week and 24th week after signing the consent.
A computational personalized cognitive therapeutic system for treating patients with Mild Cognitive Impairment, Alzheimer's Disease, dementia and related conditions is described. The system includes a patient clinical database, a data aggregation layer and data pre-processor module, a digital cognitive therapy delivery module, a cognitive analytics engine, and a personalised cognitive platform configured to personalize a personalised cognitive digital therapy model. The personalised cognitive digital therapy model defines specific digital treatments to be delivered to the patient using the digital cognitive therapy delivery module each with a different mechanism of action. A range of digital cognitive biomarkers are collected along with behavioural and physiological biomarkers from wearable and medical devices which are processed by the cognitive analytics engine and uses AI/ML methods which are configured to estimate metrics and generate alerts. The metrics are used to assess treatment progress and then personalize the personalised cognitive digital therapy model for the patient including adjustment of digital therapies and medication. Alerts may be generated if adverse side effects are observed. This process is iteratively repeated to provide improved treatment over time.
An improved rearranging composition and permanent waving process is disclosed. The improved waving process produces hair that is characterized as thicker, more full bodied with improved humectant properties and requiring significantly less maintenance than is typically required when conventional waving processes are used. The waving process is a step by step procedure involving the addition of a rearranger, a wrapping lotion, and a neutralizer, in combination with intermittent rinsing. The improved quality and settability of the hair is believed to be attributable to the improved rearranging composition. The rearranging composition comprises a homogeneous mixture of a salt of thioglycolic acid and a homopolymer of methylacrylamidopropyltrimethyl ammonium chloride (MAPTAC). A preferred rearranging composition includes a weight ratio of ammonium thioglycolate to monoethanolamine thioglycolate of from about 4:6 to about 7:3 and between about 1.0 to about 3.0% by weight of a cationic homopolymer of MAPTAC. The rearranging composition should also be pH adjusted to between about 3.0 to about 10.5.
Colorectal cancer (CRC) ranks as the third most common cancer globally and second in terms of mortality . Although CRC incidence rates are higher in high-income compared with low-to-middle-income countries (LMICs), mortality is higher in LMICs.

Extensive research within the last decade has shown that silymarin can suppress the proliferation of a variety of tumor cells; this is accomplished through cell cycle arrest at the G1/S-phase, induction of cyclin-dependent kinase inhibitors, down-regulation of anti- apoptotic gene products, inhibition of cell-survival kinases and inhibition of inflammatory transcription factors (e.g., Nuclear Factor- kappa B) through suppression of Nuclear Factor- kappa B-regulated gene products, including Cyclooxygenase-2, Lipoxygenase, Tumor necrosis factor and Interleukin-1. Silymarin can also down-regulate gene products involved in the proliferation of tumor cells (Epidermal Growth Factor Receptor, Cyclooxygenase-2), invasion (Matrix metallopeptidase 9), angiogenesis (Vascular Endothelial growth Factor) and metastasis (adhesion molecules). Silymarin was reported to alter the expression of apoptosis-related proteins including BCL2 associated X protein to induce apoptosis in human gastric cancer cells in a concentration-dependent manner. Silymarin has also been shown to sensitize tumors to chemotherapeutic agents through down-regulation of the Multidrug resistance protein and other mechanisms. In addition to its chemo-preventive effects, silymarin exhibits antitumor activity against human tumors in rodents. so we aim to assess the antitumor activity of silymarin in metastatic colorectal cancer patients receiving chemotherapy.
The invention discloses a Chinese patent medicine for treating hypertension and hyperlipidemia. The Chinese patent medicine is prepared by mixing 15 Chinese herbal medicines such as gynostemma pentaphyllum, ficus tikoua, pueraria lobata, pinus armandi franch, coix lacryma-jobi, pantropical weed root, smilax glabra roxb, honeysuckle, breynia officinalis hemsl, catsia tora linn, fallopia multiflora, crataegus pinnatifida, ophiopogon japonicus, radix scrophulariae and prunella vulgaris. The traditional Chinese medicinal syndrome differentiation proves that hyperlipidemia and hypertension diseases have characteristics of deficiency of liver-yin and kidney-yin and qi stagnation and blood stasis. The prepared Chinese patent medicine has the efficacies of benefiting yin and dispersing blood stasis, and is particularly suitable for treating hypertension and hyperlipidemia diseases. Clinical tests of applying the Chinese patent medicine to more than 8000 patients suffering from hypertension and hyperlipidemia show that the cure rate of the Chinese patent medicine can reach about 85%; and the treatment and cure time is a month and a half at least and 4 months at most. The Chinese patent medicine has the advantages of quick effectiveness, obvious curative effect, low relapse rate, no toxic and side effects, convenience in oral administrating and carrying and the like.
BACKGROUND Endoscopic biliary stent implantation is a recognized and effective method for the treatment of benign and malignant diseases of the bile duct and pancreas, ensuring smooth bile drainage. Currently, stent migration is considered a long-term and complex process, and in most cases, stents are removed through endoscopy or expelled from the body through the intestinal cavity. In rare cases, stents lead to formation of duodenocolic fistulas. CASE REPORT We report a case of duodenal colon fistula caused by a biliary stent penetrating the duodenum and entering the ascending colon. We removed the stent through endoscopy and clamped the fistulas of the colon and duodenum separately with titanium clips. Due to the presence of large common bile duct stones, nasobiliary drainage was performed again. Later, laparoscopic choledocholithotomy was performed, and the patient was discharged after rehabilitation. CONCLUSIONS ERCP endoscopy must consider the possibility of stent displacement in patients with biliary stents. In the case of CBD biliary stent dislocation in the patient, continuous abdominal plain films and physical examinations are required until spontaneous discharge is confirmed. In addition, for patients with benign bile duct stenosis undergoing biliary drainage, doctors should urge them to return to the hospital on time to remove the stent. For patients with postoperative abdominal pain or peritonitis symptoms, abdominal CT scan confirmation is required and early intervention should be considered.
FRUZAQLA can cause proteinuria. In 911 patients with mCRC treated with FRUZAQLA, 36% experienced proteinuria and 2.5% of patients experienced Grade ≥3 events. Median time to first onset of proteinuria was 22 days from first dose of FRUZAQLA.

Monitor for proteinuria before initiation and periodically throughout treatment with FRUZAQLA. For proteinuria ≥2 g/24 hours, withhold FRUZAQLA until improvement to ≤Grade 1 proteinuria, resume FRUZAQLA at a reduced dose. Discontinue FRUZAQLA in patients who develop nephrotic syndrome [see Dosage and Administration (2.2)].
Subjects will be given an Alpha-Stim inactive device for daily treatment. The electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive. The frequency on the device will state 0.5 Hz and 100 microampere but it will not actually emit anything. Subjects in this group will receive "treatment" one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur.
The carcinogenic potential of lincomycin has not been evaluated.

Lincomycin was not found to be mutagenic in the Ames Salmonella reversion assay or the V79 Chinese hamster lung cells at the HGPRT locus. It did not induce DNA strand breaks in V79 Chinese hamster lung cells as measured by alkaline elution or chromosomal abnormalities in cultured human lymphocytes. In vivo, lincomycin was negative in both the rat and mouse micronucleus assays and it did not induce sex-linked recessive lethal mutations in the offspring of male Drosophila. However, lincomycin did cause unscheduled DNA syntheses in freshly isolated rat hepatocytes.

Impairment of fertility was not observed in male or female rats given oral 300 mg/kg doses of lincomycin (0.36 times the highest recommended human dose based on mg/m2).
BACKGROUND: Dizziness often occurs after microvascular decompression (MVD), and therapeutic options are limited. The aim of this trial was to determine the potential efficacy of transcutaneous electrical acupoint stimulation (TEAS), against dizziness and its safety in patients undergoing MVD.
METHODS: Adult patients scheduled to undergo MVD for hemifacial spasm under total intravenous anesthesia were randomized at a 1:1 ratio to receive, after extubation, 30-min TEAS in the mastoid region as well as Fengchi acupoints (GB20) and Neiguan acupoints (PC6) or 30-min sham stimulation. The primary outcome was the incidence of dizziness at 2 h after surgery. Secondary outcomes included dizziness, postoperative nausea and vomiting (PONV) or headache severity, rescue medication, changes in intraocular pressure before and after surgery, length of stay, dizziness symptoms 4 weeks after discharge, and surgical complications.
RESULTS: A total of 86 patients (51.9 ± 9.4 years of age; 67 women) were enrolled. One patient (in the TEAS arm) was excluded from analysis due to conversion to sevoflurane anesthesia. The rate of dizziness at 2 h after surgery was 31.0 % (13/42) in the TEAS arm vs. 53.5 % (23/43) in the sham control arm (P = 0.036). TEAS was also associated with significantly lower severity of dizziness, based on a 10-point scale, during the first 24 h after surgery. None of the other secondary efficacy outcomes differed significantly between the two arms. All postoperative complications were Clavien-Dindo grade I or II. The rate of postoperative complications was 21.4 % (9/42) in the TEAS arm vs. 16.3 % (7/43) in the sham control arm (P = 0.544).
CONCLUSIONS: Compared with sham control, TEAS was associated with a lower incidence of dizziness within 2 h and lower severity of dizziness within 24 h post-operatively, but no improvement in other outcomes, in adult patients undergoing MVD for hemifacial spasm.
PURPOSE:To accomplish the crushing of virus particles without damaging the partial structure of the envelope by putting virus particles to high-speed collision treatment. CONSTITUTION:Virus particles, in combination with an appropriate medium (pref. liquid), are introduced into collision area through a high pressure (pref. using an air pump), the pressure is converted into flow speed by narrowing the diameter of the flow channel, and the virus particles are crushed by interaction between the impact force generated when said virus particles collide on objects in high speed within the collision area and the cavitation due to the vacuum action developed when the treating fluid passes in high speed. After the flow channel is branched into two subchannels which are then brought into a form so as to face each other, thereby enabling collision among the particles. It is preferable that the treatment be made under a pressurization of 1500-3000kg/cm<2> and at a flow speed of 500-800m/sec. By using a crushed product of the virus particles obtained through the above process, such vaccine that its immunogenicity is equal to that of the wholly particulate vaccine and the pyrogenicity has been vanished can be obtained.
PURPOSE:To obtain a composition containing a large amount of ubidecarenone, having high dispersibility, excellent bioavailability, and effective for the improvement of coronary function, by using ubidecarenone in combination with polyethylene glycol, propylene glycol, glycerol, etc. CONSTITUTION:The objective composition containing 30-95W/W% ubidecarenone is produced by compounding 1pt.wt. of ubidecarenone with >=0.05pts.wt. of a compound selected from polyethylene glycol, polyvinyl pyrrolidone, calcium carboxymethylcellulose, methylcellulose, hydroxypropylcellulose, carboxymethylcellulose, etc. In spite of high content of ubidecarenone, the composition has high dispersibility, is free from agglomeration and coagulation of particles in mixing or tableting, and can be absorbed easily through the digestive tracts. The dispersibility can be further improved by adding a surface active agent to the above composition.
Due to the current critical shortage of Dexrazoxane for Injection, 250 mg/vial and 500 mg/vial in the United States (U.S.) market, Clinigen Healthcare Ltd is coordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of Dexrazoxane for Injection 500 mg/vial.

Clinigen Healthcare Ltd has initiated temporary importation into the U.S. of Cardioxane 500 mg Powder for Solution for Infusion (dexrazoxane hydrochloride), a non-FDA approved product, to help alleviate the shortage. The Cardioxane 500 mg Powder for Solution for Infusion was manufactured by Cenexi – Laboratoires Thissen S.A. in its FDA-inspected facility in Braine l’Alleud, Belgium and is licensed for sale in the United Kingdom. Clinigen Healthcare Ltd’s distributor for Cardioxane in the US is Cumberland Pharmaceuticals Inc.

At this time, no other entities except Clinigen Healthcare Ltd and its distributor Cumberland Pharmaceutical Inc. are authorized by the FDA to import or distribute Cardioxane 500 mg Powder for Solution for Infusion in the U.S. This does not constitute an FDA approval for the Cardioxane 500 mg Powder for Solution for Infusion being distributed in the U.S.

Cardioxane 500 mg Powder for Solution for Infusion contains the same active substance, dexrazoxane hydrochloride, as FDA-approved Zinecard. It is available as 500 mg/vial (no 250 mg/vial presentation is available). It is a clinically acceptable substitute for the out of stock U.S. Dexrazoxane for Injection products. Cardioxane is available only by prescription in the U.S.

In the U.S., the labelling for Dexrazoxane Injection (Zinecard) includes the following indication: ZINECARD is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy.
Catheters used for medical treatment, e.g., hemodialysis are filled with a locking solution, usually heparin between treatments. To prevent infections, antimicrobial or antibiotic substances have been used as locking solution alone or in combination with antithrombotic substances. It has been found that these locking solutions are rapidly washed out from the catheter tip. The invention describes a thixotropic gel that can be used as locking solution. Beneficial substances, e.g., antimicrobial or antibiotic substances can be added to the gel. A preferred antimicrobial substance is taurolidin alone or in combination with salicylic acid or one of its salts.
FIELD: medicine, obstetrics and gynecology. SUBSTANCE: method involves determination of indices of systemic immunity of I and II levels in each woman by the conventional procedures being before, during and after treatment. T-activin is prescribed if T-lymphocyte level is decreased by 2-fold or more at the dose 1.0 ml, once per a day for 10 days at break for 1-1.5 month by subcutaneous route. Then the course of treatment is repeated 3-4 times up to normalization of indices. T-activin is prescribed if T-lymphocyte level is decreased less by 2-fold at the dose 1.0 ml each other day, 10 times, break is 1-1.5 month and the course is repeated once. Vilosen is prescribed at the usual regime, 2 times per a day, two courses at break for 1-2 months if T-lymphocyte level is decreased by 2-fold and more and in the presence of accompanying and often exacerbating chronic diseases of upper respiratory ways in women. Thymogen is used at the usual regime, 2 times per a day, 2-3 courses at break for 1 month up to normalization of systemic immunity indices if T-lymphocyte amount is decreased by less 2-fold and in the presence of chronic diseases of upper respiratory ways. Vilosen is prescribed by courses at the usual regime at break for 1 month at the resistant T-immunodeficiency. Sodium nucleinate is prescribed at the dose 0.2 g, 3 times for 3 days at break for 3 days and course is repeated up to normalization of indices if lymphocyte level is decreased below norma. Enterosorbents are prescribed at the usual dosage for 5-7 days at atopic response associated with food intake. Plasmaphoresis is carried out at the usual regime 1-2 times per a week, 6-8 seances if amount of circulating immune complexes is increased by above 2-fold and under control of the amount of circulating immune complexes. Blood UV-irradiation is carried at the usual regime, 1-2 times per a week for 5-7 seances if phagocytic activity is decreased. Also, during treatment period nettle dioecious decoction intake is prescribed at the usual regime for the month. EFFECT: enhanced effectiveness of treatment, decreased complications and perinatal loss in gestation and delivery. 10 cl, 2 tbl, 3 ex